<DOC>
	<DOCNO>NCT01804387</DOCNO>
	<brief_summary>Lamivudine widely use treatment-naïve chronic hepatitis B patient . However , development antiviral resistance know major drawback : Incidence lamivudine resistance report approximately 70 % 5 year ( Lok AS et al , 2003 ) . For treatment lamivudine resistance , adefovir widely use ( Lok AS McMahon B , 2009 ) . However , switch adefovir monotherapy also report high risk resistance , 25 % year 2 ( Yeon JE et al , 2006 ) . Recently , add adefovir lamivudine show superior switch adefovir monotherapy decrease adefovir resistance ( Rapti I et al , 2007 , Lampertico P et al , 2007 ) . However , combination adefovir lamivudine increase antiviral activity compare adefovir monotherapy patient lamivudine resistance ( Peters MG et al , 2004 ) . As many patient still viremic treatment lamivudine adefovir 1 year , investigator need potent combination drug . Telbivudine new nucleoside analogue potent antiviral activity . The previous phase III study show superiority telbivudine lamivudine HBeAg positive negative subject ( Lai CL et al , 2007 ) . Therefore , telbivudine plus adefovir may better treatment option lamivudine plus adefovir lamivudine-resistant chronic hepatitis B patient . No study assess efficacy telbivudine plus adefovir conducted patient . The aim study evaluate safety efficacy telbivudine plus adefovir compare lamivudine plus adefovir lamivudine resistant chronic hepatitis B patient end 1 year follow-up ,</brief_summary>
	<brief_title>Comparison Telbivudine Plus Adefovir With Lamivudine Plus Adefovir Treatment Lamivudine-resistant Chronic Hepatitis B 52 Weeks : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . HBeAg positive negative chronic hepatitis B patient ( positive HBsAg 6 month ) 2 . Age ≥ 18 year old , ≤70 year old 3 . Previous treatment lamivudine 6 month 4 . Being lamivudine time screen 5 . Confirmed genotypic resistance lamivudine RFMP ( rtM204V I ) 6 . Presence virologic breakthrough ≥1 log increase HBV DNA na dir ) 7 . HBV DNA ≥ 20,000 IU/mL 8 . Patient willing give inform consent ( If patient &lt; 20 year old , parent legal guardian also need give informed consent ) 1 . Out inclusion criterion 2 . Presence adefovir resistance ( rtA181T V , rtN236T ) RFMP assay 3 . Laboratory abnormality follow screening : AFP &gt; 100 ng/mL , serum phosphorous level &lt; 2.4 mg/dL , serum creatinine level &gt; 1.5 mg/dL creatinine clearance &lt; 50 mL/min 4 . Patient history decompensated liver disease : Any patient history ascites , hepatic encephalopathy , variceal bleeding , jaundice , CTP &gt; 7 point exclude . 5 . History treatment nucleos ( ) ide analogue lamivudine 4 week 6 . History immune modulatory drug ( interferon , thymosinalfa ) within 24 week screen 7 . Liver transplant patient 8 . Patient coinfected HIV , HCV , HDV 9 . Patient metabolic genetic liver disease may affect serum ALT level 10 . Habitual alcohol consumption ( &gt; 140 g/week male , &gt; 70 g/week female ) 11 . Patient able stop drug may affect ALT HBV DNA level study period ( ie . Steroid , immunesuppressants , nonsteroidal antiinflammatory drug , acetaminophen , ) 12 . Pregnant lactate woman 13 . Menstruating woman unwilling use appropriate method contraception ( ie . Condom , oral contraceptive , tubal ligation ) 14 . Patient hepatocellular carcinoma ( treat treat ) 15 . Patient untreated malignancy 16 . Patient history malignancy cure within 5 year screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Telbivudine</keyword>
	<keyword>Adefovir</keyword>
	<keyword>Lamivudine resistance</keyword>
</DOC>